Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1528

Sort by

Sort Order Select

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Zhigang Cai, PhD, Baskar Ramdas, PhD, Jonathan Kotzin, Martin P. Carroll, MD, Gerald Wertheim, MD, PhD, Adam Williams, Jorge Henao-Mejia, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 915.

https://doi.org/10.1182/blood-2019-130653

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

ATM Germline Variant Increases the Risk of MPN Progression

Theodoros Karantanos, MD PhD, Shruti Chaturvedi, MBBS, MS, Christopher D Gocke, MD, Donna Marie Williams, PhD, Alison R. Moliterno, MD, Evan M Braunstein, MD PhD

Blood (2019) 134 (Supplement_1): 835.

https://doi.org/10.1182/blood-2019-125362

Published: 2019

Journal Articles

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Theodoros Karantanos, MD PhD, Evan M Braunstein, MD PhD, Shruti Chaturvedi, MBBS, MS, Jerry L. Spivak, MD, Linda Resar, MD, Styliani Karanika, MD, Donna Marie Williams, PhD, Christopher D Gocke, MD, Alison R. Moliterno, MD

Blood (2019) 134 (Supplement_1): 837.

https://doi.org/10.1182/blood-2019-125393

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting

Christopher R Frei, Hannah Le, PharmD, MPH, Daniel McHugh, Cynthia Elesinmogun, PharmD, Samantha Galley, Kathleen Franklin, Juan Tavera, Michelle Janania Martinez, MD, David J Gregorio, DO, Snegha Ananth, MBBS, Ricardo Uribe, Prathibha Surapaneni, Manuel Ricardo Espinoza-Gutarra, MD, Michael Song, Xavier Jones, Chengwen Teng, Obiageri O Obodozie-Ofoegbu, Zohra Nooruddin, MD

Blood (2019) 134 (Supplement_1): 795.

https://doi.org/10.1182/blood-2019-122434

Published: 2019

Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Blood (2019) 134 (Supplement_1): 830.

https://doi.org/10.1182/blood-2019-131494

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

Magali Le Garff-Tavernier, Agathe Pruvot Debliquis, PharmD, Thomas Boyer, MD, Jean-Philippe Vial, MD, Véronique Harrivel, MD, Anne-Catherine Lhoumeau, PhD PharmD, Marie-Christine Jacob, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD, Bernard Drenou, MD PhD, Orianne Wagner Ballon, MD PhD

Blood (2019) 134 (Supplement_1): 1218.

https://doi.org/10.1182/blood-2019-123415

Published: 2019

Journal Articles

B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL

Gregory Lazarian, PharmD, Shanye Yin, PhD, Elisa Ten Hacken, PhD, Tomasz Sewastianik, MSc,PhD, Alba Font-tello, PhD, Heather Joyal, Elizabeth Witten, Mei Zheng, Christopher J. Ott, PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Ruben D. Carrasco, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 848.

https://doi.org/10.1182/blood-2019-123963

Published: 2019

Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 823.

https://doi.org/10.1182/blood-2019-125136

Published: 2019

Journal Articles

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 738.

https://doi.org/10.1182/blood-2019-128909

Published: 2019

Journal Articles

Development of the First Transgenic Animal Model for IRF4-Induced Lymphoid Malignancy

Stella Amanda, MSc, BSc, Regina Wong, Tze King Tan, PhD, Muhammad Zulfaqar Ali, MSc, BSc, Yan Li, PhD, Zhi Yuan Gong, PhD, Shinsuke Iida, MD PhD, Takaomi Sanda, MD PhD

Blood (2019) 134 (Supplement_1): 1242.

https://doi.org/10.1182/blood-2019-129714

Published: 2019

Journal Articles

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Christopher J. Walker, PhD, Ann-Kathrin Eisfeld, MD, Hatice G Ozer, PhD, Jessica Kohlschmidt, PhD, Deedra Nicolet, Krzysztof Mrózek, MD PhD, Dimitrios Papaioannou, MD, Luke K Genutis, BS, Bayard L Powell, MD, Geoffrey L. Uy, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard Stone, MD, Ramiro Garzon, MD, John C. Byrd, MD, Albert de la Chapelle, MD PhD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 1247.

https://doi.org/10.1182/blood-2019-127478

Published: 2019

Journal Articles

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability

Blood (2019) 134 (Supplement_1): 729.

https://doi.org/10.1182/blood-2019-122784

Published: 2019

Journal Articles

Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)

Blood (2019) 134 (Supplement_1): 2700.

https://doi.org/10.1182/blood-2019-127475

Published: 2019

Journal Articles

MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry

Kiyoshi Okazuka, MD, Tadao Ishida, MD PhD, Jun Sakamoto, Nobuhiro Tsukada, MD PhD, Kenshi Suzuki, MD PhD

Blood (2019) 134 (Supplement_1): 1832.

https://doi.org/10.1182/blood-2019-123900

Published: 2019

Journal Articles

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Joseph Tripodi, Douglas Tremblay, MD, Ronald Hoffman, MD, Umut Ozbek, PhD, John Mascarenhas, MD, Marina Kremyanskaya, Vesna Najfeld, PhD

Blood (2019) 134 (Supplement_1): 1687.

https://doi.org/10.1182/blood-2019-128948

Published: 2019

Journal Articles

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Blood (2019) 134 (Supplement_1): 1619.

https://doi.org/10.1182/blood-2019-131435

Published: 2019

NARROW

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

ATM Germline Variant Increases the Risk of MPN Progression

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Development of the First Transgenic Animal Model for IRF4-Induced Lymphoid Malignancy

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability

Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)

MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only